Literature DB >> 19534466

A non-chromatographic method for the purification of a bivalently active monoclonal IgG antibody from biological fluids.

Başar Bilgiçer1, Samuel W Thomas, Bryan F Shaw, George K Kaufman, Vijay M Krishnamurthy, Lara A Estroff, Jerry Yang, George M Whitesides.   

Abstract

This paper describes a method for the purification of monoclonal antibodies (rat anti-2,4-dinitrophenyl IgG: IgG(DNP); and mouse antidigoxin IgG: IgG(Dgn)) from ascites fluid. This procedure (for IgG(DNP)) has three steps: (i) precipitation of proteins heavier than immunoglobulins with ammonium sulfate; (ii) formation of cyclic complexes of IgG(DNP) by causing it to bind to synthetic multivalent haptens containing multiple DNP groups; (iii) selective precipitation of these dimers, trimers, and higher oligomers of the target antibody, followed by regeneration of the free antibody. This procedure separates the targeted antibody from a mixture of antibodies, as well as from other proteins and globulins in a biological fluid. This method is applicable to antibodies with a wide range of monovalent binding constants (0.1 microM to 0.1 nM). The multivalent ligands we used (derivatives of DNP and digoxin) isolated IgG(DNP) and IgG(Dgn) from ascites fluid in yields of >80% and with >95% purity. This technique has two advantages over conventional chromatographic methods for purifying antibodies: (i) it is selective for antibodies with two active Fab binding sites (both sites are required to form the cyclic complexes) over antibodies with one or zero active Fab binding sites; (ii) it does not require chromatographic separation. It has the disadvantage that the structure of the hapten must be compatible with the synthesis of bi- and/or trivalent analogues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19534466      PMCID: PMC2845436          DOI: 10.1021/ja9023836

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  33 in total

1.  Drug discovery: a historical perspective.

Authors:  J Drews
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

2.  Mimotopes: realization of an unlikely concept.

Authors:  R H Meloen; W C Puijk; J W Slootstra
Journal:  J Mol Recognit       Date:  2000 Nov-Dec       Impact factor: 2.137

Review 3.  Therapeutic antibodies for human diseases at the dawn of the twenty-first century.

Authors:  Ole Henrik Brekke; Inger Sandlie
Journal:  Nat Rev Drug Discov       Date:  2003-01       Impact factor: 84.694

4.  Dimerization kinetics of the IgE-class antibodies by divalent haptens. I. The Fab-hapten interactions.

Authors:  R Schweitzer-Stenner; A Licht; I Pecht
Journal:  Biophys J       Date:  1992-08       Impact factor: 4.033

5.  Dissociation kinetics of bivalent ligand-immunoglobulin E aggregates in solution.

Authors:  R G Posner; J W Erickson; D Holowka; B Baird; B Goldstein
Journal:  Biochemistry       Date:  1991-03-05       Impact factor: 3.162

6.  Antibody affinity. 3. The role of multivalance.

Authors:  C L Hornick; F Karuch
Journal:  Immunochemistry       Date:  1972-03

Review 7.  Concepts and progress in the development of peptide mimetics.

Authors:  G L Olson; D R Bolin; M P Bonner; M Bös; C M Cook; D C Fry; B J Graves; M Hatada; D E Hill; M Kahn
Journal:  J Med Chem       Date:  1993-10-15       Impact factor: 7.446

8.  Theory of equilibrium binding of symmetric bivalent haptens to cell surface antibody: application to histamine release from basophils.

Authors:  M Dembo; B Goldstein
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

9.  Oligomerization and ring closure of immunoglobulin E class antibodies by divalent haptens.

Authors:  R Schweitzer-Stenner; A Licht; I Lüscher; I Pecht
Journal:  Biochemistry       Date:  1987-06-16       Impact factor: 3.162

10.  Bivalent ligand dissociation kinetics from receptor-bound immunoglobulin E: evidence for a time-dependent increase in ligand rebinding at the cell surface.

Authors:  J W Erickson; R G Posner; B Goldstein; D Holowka; B Baird
Journal:  Biochemistry       Date:  1991-03-05       Impact factor: 3.162

View more
  7 in total

1.  Design of a heterotetravalent synthetic allergen that reflects epitope heterogeneity and IgE antibody variability to study mast cell degranulation.

Authors:  Michael W Handlogten; Tanyel Kiziltepe; Basar Bilgicer
Journal:  Biochem J       Date:  2013-01-01       Impact factor: 3.857

2.  Selective precipitation and purification of monovalent proteins using oligovalent ligands and ammonium sulfate.

Authors:  Katherine A Mirica; Matthew R Lockett; Phillip W Snyder; Nathan D Shapiro; Eric T Mack; Sarah Nam; George M Whitesides
Journal:  Bioconjug Chem       Date:  2012-01-26       Impact factor: 4.774

3.  Accessing lipophilic ligands in dendrimer-based amphiphilic supramolecular assemblies for protein-induced disassembly.

Authors:  Volkan Yesilyurt; Rajasekharreddy Ramireddy; Malar A Azagarsamy; S Thayumanavan
Journal:  Chemistry       Date:  2011-11-30       Impact factor: 5.236

4.  A heterobivalent ligand inhibits mast cell degranulation via selective inhibition of allergen-IgE interactions in vivo.

Authors:  Michael W Handlogten; Ana P Serezani; Anthony L Sinn; Karen E Pollok; Mark H Kaplan; Basar Bilgicer
Journal:  J Immunol       Date:  2014-01-31       Impact factor: 5.422

5.  Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation.

Authors:  Michael W Handlogten; Tanyel Kiziltepe; Ana P Serezani; Mark H Kaplan; Basar Bilgicer
Journal:  Nat Chem Biol       Date:  2013-10-06       Impact factor: 15.040

6.  Supramolecular disassembly of facially amphiphilic dendrimer assemblies in response to physical, chemical, and biological stimuli.

Authors:  Krishna R Raghupathi; Jing Guo; Oyuntuya Munkhbat; Poornima Rangadurai; S Thayumanavan
Journal:  Acc Chem Res       Date:  2014-06-17       Impact factor: 22.384

7.  Redox Dual-Responsive and O2‑Evolving Theranostic Nanosystem for Highly Selective Chemotherapy against Hypoxic Tumors.

Authors:  Huachao Chen; Fei Li; Yongrong Yao; Zhe Wang; Zhihao Zhang; Ninghua Tan
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.